Anti-PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status.
Taichi MatsubaraTakashi SetoShinkichi TakamoriTakatoshi FujishitaRyo ToyozawaKensaku ItoMasafumi YamaguchiTatsuro OkamotoPublished in: OncoTargets and therapy (2021)
Anti-PD-1 therapy had similar efficacy in older and younger patients with NSCLC, whereas survival was significantly worse in patients with poor PS. However, immune checkpoint inhibitors may be considered for patients with poor PS harboring positive PD-L1 expression.